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Abstract 
We studied the androgen receptor gene in a large kindred with complete androgen insensitivity syndrome and negative receptor- 
binding activity. single-strand conformation polymorphism (SSCP) analysis and sequencing identified a 13 base pair deletion within 
exon 4. This was responsible for a predictive frameshift in the open reading frame and introduction of a premature stop codon at 
position 783 instead of 919. The deletion was reproduced in androgen receptor wildtype cDNA and transfected into mammalian cells. 
Western blot showed a smaller androgen receptor of 94 kDa for the transfected mutated cDNA instead of 110 kDa. Androgen-binding 
assay of the mutated transfected cells assessed the lack of androgen-binding. Gel retardation assay demonstrated the ability of the 
mutant to bind target DNA ; however, the mutant was unable to transactivate a reporter gene. Although the role of the partial deletion in 
the lack of androgen action was expected, in vitro analyses highlight the role of the abnormal C-terminal portion in the inhibition of the 
receptor transregulatory activity of the protein causing androgen resistance in this family. 
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1. Introduction 
The syndrome of testicular feminization or complete 
androgen insensitivity syndrome (CAIS) is an X-linked 
disorder characterized by a female phenotype along with 
the failure of Wolffian development in karyotypically 
46,XY individuals with intraabdominal or inguinal testes, 
which are able to normally synthesize androgens (Brown 
and Migeon, 1987). Individuals with CAIS usually come 
to medical attention because of inguinal hernia or primary 
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amenorrhea at puberty. The phenotype is female with 
diminished or absent axillary and pubic hair. This disease 
results from a defective cellular response to androgens 
due to a non-functional androgen receptor (AR), the me- 
diator of androgen action in cells (Brown and Migeon, 
1987). Cloning and sequencing of the AR gene (Chang et 
al., 1988; Lubahn et al., 1988; Trapman et al., 1988) lo- 
cated on the X chromosome demonstrated that the AR 
belongs to a subfamily of steroid hormone receptors 
within a large superfamily of ligand-responsive DNA- 
binding transcription factors which share a homology of 
structure (Evans, 1988). The AR is composed of an 
amino-terminal domain encoded by the large exon 1, 
which plays a role in transcriptional activation; a central 
cysteine-rich DNA-binding domain, composed of two 
zinc-fingers encoded by exons 2 and 3, respectively; and 
a carboxy-terminal region, encoded by exons 4-8, in- 
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volved in ligand binding and in the interactions with sev- 
eral heat-shock proteins (HSP) (Evans, 1988). There are 
few data concerning the secondary and tertiary structures 
of the AR or the proteins that interact with it to induce 
enhancement of androgen-regulated gene transcription. 
Development of molecular tools to analyze mutant AR 
genes in CAIS would thus be useful for studying the 
structure-function relationship of the AR. 
Molecular study of patients with CAIS has revealed a 
large spectrum of point mutations contrasting with a low 
frequency of gene deletion (McPhaul et al., 1993; Sultan 
et al., 1993; Patterson et al., 1994; Zhou et al., 1994). 
Southern blot or enzymatic amplification analyses have 
shown only eight complete or partial AR gene deletions 
associated with CAIS (Brown et al., 1988; Ris-Stalpers et 
al., 1990; Trifiro et al., 1991; Batch et al., 1992; Quigley 
et al., 1992a,b; MacLean et al., 1993; Beitel et al., 1994). 
Extensive gene rearrangements thus do not appear to ac- 
count for a large percentage of patients. Indeed, in a pre- 
vious work on 40 families, we found no deletions 
(Lobaccaro et al., 1992; and unpublished data). 
In a large kindred with complete androgen insensitivity 
syndrome, we found a partial deletion in exon 4, encoding 
part of the carboxy-terminal domain of the AR. To spec- 
ify the defect of the AR at the molecular level, we ana- 
lyzed the consequences of the deletion on the protein size 
and on the AR functional properties, i.e. androgen- and 
DNA-binding ability along with reporter gene transacti- 
vation capacity. 
2. Family and methods 
2.1. Family 
We studied a French family presenting four cases of 
CAIS (Fig. 1). Patient III-2 had originally been referred to 
the Department of Pediatrics of Clermont-Ferrand at 
14 years of age, for the presence of an oblong mass in the 
labia majora. The diagnosis of CAIS was based on the 
association of primary amenorrhea, absence of pubic and 
axillary hair, normal breast development in this pheno- 
typical adolescent girl with a 46,XY blood karyotype, and 
a plasma testosterone concentration of 3.5 nmol/l (normal 
value for a Tanner stage III normal boy). The same diag- 
nosis was made for patients 111-4, III-6 and 111-7, present- 
ing bilateral inguinal hernia, female phenotype and 
46,XY karyotype. The right gonad of III-4 had been re- 
moved. Pathological examination showed small and 
regular seminiferous tubes with Sertoli cells and few 
germinal cells. Interstitial tissue was abundant, hyper- 
plastic and composed of Leydig cells. The four patients 
had refused the prophylactic removal of their gonads. 
Fifteen years later, plasma testosterone showed high val- 
ues of 33.0, 16.5, 27.0 and 26.5 nmol/l (normal range 
from 12.0 to 24.0 nmol/l for adult males) for patients III-2 
(29 years), III-4 (23 years), III-6 (20 years) and III-7 
(18 years) respectively, confirming the presence of func- 
tioning testes. We had previously performed an androgen- 
binding study in the genital skin fibroblasts of patient III- 
4. The number of binding sites and the dissociation con- 
stant of the AR were determined from Scatchard analysis 
using 17-methyl-[3H]-R1881 (17p-hydroxy-17a-methyl- 
4,9,11-estratrien-3-one, DuPont de Nemours, France) as 
ligand. AR-binding capacity was undetectable (the nor- 
mal mean for AR concentrations in genital skin fibro- 
blasts is 650 ? 200 fmol/mg DNA). 
Moreover, the mother, II-l, had three sisters, 11-3, II-4 
and II-6 with primary amenorrhea, absence of pubic and 
axillary hair, and infertility suggesting the diagnosis of 
CAIS. They refused to be further examined and were un- 
available for any blood karyotyping and/or DNA investi- 
gations. 
2.2. Single-strand conformation polymorphism analysis 
and direct sequencing 
Genomic DNA of patient III-7 was extracted from pe- 
ripheral blood lymphocytes by phenol-chlorophorm ex- 
traction and ethanol precipitation, and the eight exons of 
the AR gene were amplified by enzymatic amplification 
(PCR) and analyzed by single-strand conformation poly- 
morphism (SSCP) methods as previously described 
(Lobaccaro et al., 1993). PCR products of exon 4 were 
purified after 2% Nusieve gel electrophoresis (FMC, 
Fig. 1. Pedigree of the family. Black square indicates affected 46,XY patient. Circle with dot indicates obligate heterozygote; Square with question 
mark indicates potentially affected 46,XY patient. Lined arrow head indicates infertility. 
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USA) and phenol-chloroform extraction. Sequencing 
reactions were repeated twice with two different PCR 
products with the same primers used for PCR (AR4S, 5’ 
GCATTGTGTGTTFITGACCACTG 3’ and AR4A 5’ 
CCCCCTTATCTCATGCTCCC 3’) according to Lum- 
broso et al. (1993). 
2.3. Construction of AR cDNA expression vector with the 
deleted exon 4 
The wildtype human AR cDNA expression vector was 
a generous gift from Dr. T.R. Brown (Johns Hopkins 
University, Baltimore, MD). In this construct (termed 
pCMV5-hAR), receptor cDNA insert was cloned between 
the BglII and BamHI sites of pCMV5 vector (Brown et 
al., 1990). To obtain the mutant vector, a KpnI-BumHI 
fragment (containing both DNA and androgen-binding 
domain) was cleaved from pCMVS-hAR and subcloned 
into the corresponding sites of pUC 19 (pUC 19-hAR). The 
PCR of the patient’s exon 4 was digested by Tthl 111 and 
S&I. The Tthl 1 I-I/Std fragment was purified on Nusieve 
gel and ligated to pUC19-hAR, whose normal Tthl 1 l-I/ 
StuI fragment had been previously cleaved. Finally, the 
deleted exon 4 KpnI-BamHI fragment was inserted into 
the corresponding sites of pCMV5-hAR to yield pCMVS- 
hAR-de14. All amplifications were performed in DH5a 
cells and all steps were verified by sequencing the whole 
exon 4. 
2.4. Androgen-binding assay 
COS-7 cells were cultured in Dulbecco’s minimal es- 
sential medium (DMEM Gibco-Brl, France) and 10% 
fetal calf serum (FCS), penicillin (100 units/ml), and 
streptomycin (100 pg/ml). Cells ( 106) were transiently 
transfected with 2Opg of either plasmid construct 
pCMVS-hAR or pCMVS-hAR-dell by the calcium phos- 
phate co-precipitation method, cultured for 2 days in 10% 
charcoal-steroid depleted FCS and then incubated for 1 h 
at 37°C with 0.2, 0.4, 0.67, 1.0, 1.5 and 2.5 nM r3HJ- 
R1881. The constant of dissociation was determined as 
previously described (Sultan et al., 1983). 
2.5. Western blot analysis 
Transfected COS-7 cells were lysed in 50~1 of 65 mM 
Tris-HCl (pH 6.8), 500 mM DTT, SDS 5%, and 5 M 
urea. After boiling for 10 min and centrifugation at 
13 000 rev./min for 10 min, one-third of the supernatant 
was electrophoresed in SDS/PAGE and blotted and im- 
munostained with antibody SpO61 (diluted 1:2000), a 
polyclonal antibody directed against the N-terminal do- 
main of the human AR, as previously described (van Laar 
et al., 1989). 
2.4. Gel-retardation assay 
COS-7 (8 X 105) cells transfected with 10,ug of 
plasmid were incubated with lOA M R188 1 for 24 h, 
lysed in 60~1 of 10 mM Tris-HCl (pH 7.5), EDTA 
1 mM, DTT 1 mM, KC1 400 mM, glycerol 10% (KC1 
buffer), leupeptine 1.9 mM, pepstatine 1.32 mM, apopro- 
tein 0.14 mM, PMSF 41 mM, chymostatine 2 mM and 
antipaine 2 mM (anti-proteases) by three cycles of freeze- 
thawing. Cells were then centrifuged at 4°C at 
6000 rev./min for 1 min and the supernatant recovered. 
The interaction of androgen-AR complexes with target 
DNA was studied by a mobility shift assay using syn- 
thetic complementary oligonucleotide probe obtained by 
annealing the single-strand oligonucleotides 5’ GATCTC- 
AGAACACTGTGTTCTGA 3’ and 5’ CTAGTCAGA- 
ACACAGTGTICTGA 3’) containing a glucocorticoid 
response element (GRE, underlined sequences) derived 
from the sequence of the GRE previously defined in the 
mouse mammary tumor virus (Payvar et al., 1983). Two 
microliters of this cell extract were incubated at 4°C in an 
equal volume of KC1 50 mM, K3P0, 20 mM (pH 7.4), 
MgCl* 1 mM, P-mercaptoethanol 1 mM, glycerol 20% 
and 2pg of poly [d(I-C)] to avoid unspecific binding, for 
15 min. In certain tubes, SP061 antibody was added and 
incubated for 15 min at 4°C. Last, 10 000 cpm of the 
probe, labeled with Klenow polymerase and [a32P]-dCTP 
to a specific activity of at least lo7 cpm/pg, was added for 
15 min. Electrophoresis was performed on 4.5% acryla- 
mide gel (acrylamide/bisacrylamide, 38: l), TBE 0.25 X 
(TBE 1 X: 0.1 M Tris-HCl, pH 8.0, 0.083 M boric acid, 
20 mM EDTA) at 20 mA for 90 min in a cold room. The 
gel was then dried and autoradiographed for 24 h with an 
intensifying screen. 
2.7. Luciferase activity and a-galactosidase 
For transcription studies, 2 X lo5 CV-1 cells were 
transfected with 100 ng of either pCMV5-hAR or 
pCMVS-hAR-de14, 500 ng of pTAT-TK-Luc, a reporter 
plasmid construct [firefly structural luciferase gene under 
control of rat tyrosine amino transferase promoter], and 
500 ng of pCMV5#-galactosidase, an internal control 
plasmid. Transfected CV-1 cells were cultured for 1 day 
in 10% charcoal-steroid depleted FCS, incubated for 
1 day with various concentrations of DHT (lOeg and 
10e8 M) or ethanol as control, and then lysed in 300~1 of 
25 mM Tris-HCl (pH 7.8), 2 mM EDTA, 2 mM DlT, 
10% glycerol and 1% Triton X- 100 final solution. Extract 
(100~1) was added to 100~1 of 270pM coenzyme A 
(lithium salt), 470pM luciferine, 530pM ATP, 20 mM 
Tris-H3P04 (pH 7.8) 1.05 mM MgCl*, 2.7 mM MgSO,, 
0.1 mM EDTA, and 33 mM DTT. Luciferase activity was 
measured on an LKB luminometer. /?-Galactosidase was 
assayed on 50~1 of cell extract. The standard assay was 
performed by adding an equal volume of the assay 2X 
buffer (200 mM sodium phosphate, pH 7.3, 2 mM MgCl,, 
100 mM b-mercaptoethanol) which contained 1.33 g/l of 
substrate o-nitrophenyl-/?-D-galactopyranoside. Samples 
were incubated for 60 min. Absorbance at 420 nm was 
read after addition of 500~1 of Na2C0, with a spectro- 
photometer. 
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Fig. 2. Partial sequence of androgen receptor exon 4 of patient III-7 compared to C. The deleted 13 base pairs are boxed. Single-letter amino acid code 
is used and the number of amino acids is indicated in the margins (according to Lubahn et al., 1989). 
3. Results 
3.1. Ident$cation of the partial AR gene deletion in exon 
4 
Evaluation of exons amplified by polymerase chain re- 
action, using a 1.2% agarose gel electrophoresis to de- 
termine product size, revealed no gross abnormalities in 
either patient III-7 or a control for exons l-8. To screen 
for minor gene alterations, amplified exons were further 
investigated by SSCP analysis. SSCP indicated a mobility 
shift in exon 4 (data not shown), suggesting a sequence 
alteration. As shown in Fig. 2, sequence analysis of exon 
4 revealed a 13 base pair deletion from position 29 11 to 
2923 (between Leu707 and Gln7 11, sequence numeration 
according to Lubahn et al. (1989)). This partial deletion 
created a shift in the open reading frame that interfered 
with the translation of downstream exons. Moreover, a 
premature stop codon was introduced at position 783. 
Translation of the deleted AR mRNA would thus result in 
an abnormal and C-terminal truncated protein (782 amino 
acids versus 9 19 in the wildtype AR). 
3.2. Western blot of the transfected mutant AR 
To investigate whether the deleted gene could be 
translated and to calculate the size of the AR protein pro- 
duced, an AR-deleted expression vector was constructed 
since the original fibroblasts were lost and the family did 
not consent to another genital skin biopsy. After transient 
expression in COS-7 cells, SDS-PAGE and western blot, 
the presence of comparable amounts of the wildtype 
(110 kDa, calculated molecular mass 99 kDa) and mutant 
(94 kDa, calculated molecular mass 82 kDa) proteins was 
demonstrated (Fig. 3). The discrepancy of approximately 
12 kDa between calculated and SDS-PAGE apparent 
masses was probably due to structural aspects of the N- 
terminal domain which influences the mobility on SDS- 
PAGE; indeed, deletions or truncations at the C-terminal 
part still have this discrepancy of 12 kDa. 
3.3. Androgen-binding capacity of the mutant AR 
To confirm that the mutant lacked the carboxy- 
terminal function, androgen binding was examined by 
whole cell binding of [“H]R1881 in COS-7 cells. The 
dissociation constant (Kd) of the pCMVS-hAR-de14 vec- 
tor product was undetectable whereas the transfected 
wildtype showed a Kd of 0.5 nM (N = 0.5 f 0.3 nM) (data 
not shown). 
3.4. DNA-binding properties of the mutant AR 
In order to study the DNA-binding capacity of the de- 
leted AR, gel shift assays were performed. No differences 
in the DNA-binding property were found between the 
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Fig. 3. Immunowestem blot analysis of pCMVS-AR protein, the 
wildtype AR, and pCMVS-AR-del4, with the deleted AR expressed in 
COS-7 cells and immunostained with antibody SpO61. The protein 
band of around 50-60 kDa is probably due to proteolytic breakdown. 
wildtype and the mutant AR (Fig. 4). Additionally, the gel 
retardation experiments performed after pre-incubation of 
the AR with an antibody that recognizes N-terminal se- 
quence (van Laar et al., 1989) showed a supershift of the 
receptor-DNA complex generated by the wildtype recep- 
tor with the GRE. This confirmed that the retardation was 
not artefactual. This supershift was also observed for the 
deleted receptor (Fig. 4) and, as already observed by other 
groups (De Vos et al., 1994), the addition of the antibody 
enhanced the interaction of AR with target DNA. It was 
hypothesized that the antibody stabilizes either dimeriza- 
tion of the AR or a conformation conducive to DNA 
binding. 
3.5. Capacity of the deleted receptor to stimulate the rat 
tyrosine amino transferase promoter 
To highlight the capacity of the mutant AR to stimu- 
late androgen-responsive genes, transcriptional activity 
was determined in the co-transfection assay in CV-1 cells 
by enhancement of luciferase activity with various con- 
centrations of androgen. Data are expressed as arbitrary 
units, corrected by the level of /I-galactosidase activity. In 
the presence of androgens, CV-I cells transfected with 
pCMVS-hAR demonstrated the presence of a hormone- 
induced luciferase activity. However, CV-1 cells trans- 
fected with pCMVS-hAR-de14 did not show any lu- 
ciferase activity in the presence of various concentrations 
of DHT compared to cells incubated with ethanol or non- 
pCMV5-hAR pCMVS-hAR-de14 
I 
1 2 
e super-shifted band 
rl- shifted band 
Fig. 4. Mobility shift assay. Shift bands corresponding to the wildtype pCMVS-AR are visible in lanes 14. Shift bands corresponding to pCMVS-AR- 
de14 are visible in lanes 5-8. Bands m lanes 3, 4 and 7, 8 are supershifted by the anti-AR SpO61 (diluted 1:2000) (van Laar et al., 1989). 
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Fig. 5. Enhancement of pTAT-TK-Luc transcription CV-1 cells co- 
transfected with pCMV5-hAR or pCMV5-hAR-de14. Cells were incu- 
bated with DHT at 10-8, 10d9 M, or ethanol (EtOH); NT, non- 
transfected cells. The luciferase activity, mean of two values, is indi- 
cated in arbitrary units, corrected by /%galactosidase activity. 
transfected cells (Fig. 5). These data indicate that the 
mutant receptor is not constitutively active. 
4. Discussion 
The action of androgens on target cells occurs via the 
classical and complex steroid receptor pathway. Any gene 
alterations of the AR that impair androgen action are thus 
responsible for androgen insensitivity syndrome. As far as 
we know, few AR gene rearrangements, such as deletions, 
have been described in CAIS, whereas nearly 100 AR 
gene point mutations have been reported (for review see 
McPhaul et al., 1993; Sultan et al., 1993; Patterson et al., 
1994; Zhou et al., 1994). The AR gene rearrangement we 
describe is the first partial exon 4 deletion which causes a 
frameshift in the open reading frame and, is associated 
with CAIS. Exon 4 is rarely affected by gene rearrange- 
ments: indeed, to date, only four amino acid missense 
mutations and one trinucleotide deletion without frame- 
shift have been reported in patients with CAIS. Con- 
versely, a surprising deletion of the entire exon 4 has been 
described by Akin et al. (1991) using PCR in a man with 
an isolated azoospermia. How a complete exon deletion 
causes such a minor form of AIS while point mutations of 
the same exon cause the complete form has not been elu- 
cidated. 
The deletion we describe here introduces a premature 
stop codon after a frameshift (Fig. 6). Two other frame- 
shifts have been described in patients with CAIS by Batch 
et al. ( 1992) in the large exon 1. The authors reported a 
single deletion mutant at position 127 and a four nucleo- 
tide insertion at position 202. It is interesting to note that 
c DNA-binding - androgen-regulated gene 
expression 
AF-2a HSP90-binding 
628 673 693 720 774 
t 
919 
- 
f 
0 TAF,,-30 
( - -t absence of gene 
, expression 
deleted AR (this study) 
Fig. 6. Hypothetical consequences of the frameshift on the transcriptional capacity of the deleted AR. Schematic representation of the androgen- 
binding domain of both wildtypc and deleted AR. AF-2a (Fierrat et al., 1994) and HSP-binding site (Marivoct et al., 1992) are indicated. The number- 
ing is according to Lubahn et al. (1989). Dotted area indicates abnormal amino acid sequence. The foreign C-terminal amino acids would inhibit the 
TAFn-30 binding to AF-2a and causes the inactivity of the truncated AR in the absence of hormone. 
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a reinitiation of translation at methionine residue sites 
downstream of a frameshift mutation has been described 
in Tfm mice (Young et al., 1989; Charest et al., 1991; 
Gaspar et al., 1991) and in a patient with CAIS (Zoppi et 
al., 1992). Even though reinitiation is inefficient, it leads 
to the synthesis of low levels of a receptor comprising the 
DNA- and androgen-binding domains. Reinitiation thus 
leads to the production of low levels of N-terminal trun- 
cated AR with androgen-binding activity. In the mutant 
we describe, reinitiation of translation could theoretically 
occur at several ATG triplets, independently of the open 
reading frame (at position 734, 742, 745, 749, etc. of the 
wildtype AR) and, to test this hypothesis, the use of anti- 
body against the end of the C-terminal domain would be 
useful. 
In vitro analyses have shown that the deleted AR does 
not bind androgens and that it is incapable of inducing 
transactivation of androgen-regulated genes. These results 
indicate that this gene alteration caused androgen resis- 
tance in this family. Ris-Stalpers et al. (1990) reported a 
mutant AR presenting an aberrant splicing site, introduc- 
ing a 123 bp deletion in the mRNA responsible for the 
presence of the portion from amino acid 683 to 723 
(numbering according to Lubahn et al., 1989) and that it 
is unable to transactivate androgen-regulated genes. Inter- 
estingly, Simental et al. (1991) demonstrated that AR 
lacking the end portion of the androgen-binding domain 
from amino acid 660 may show constitutive transcrip- 
tional activity of 13%, as described for androgen (Jenster 
et al., 1991) or other steroid receptors (Evans, 1988). 
Analysis of discrepancies in constitutive transcriptional 
activity among mutant ARs described by Ris-Stalpers et 
al. and by ourselves, and the one studied by Simental et 
al. raised several questions in terms of AR structure- 
function relationship. Firstly, a low expression of mutant 
AR in our experiments can be ruled out since comparable 
amounts of the wildtype and mutant proteins has been 
shown by western blot (Fig. 2). Secondly, involvement of 
modification of HSP90 binding can be questioned. In- 
deed, the binding of HSP to AR is supposed to play a role 
in the inhibition of transcription capacity in the absence 
of ligand (Veldscholte et al., 1992). The common part 
found in the mutants described by Ris-Stalpers et al. and 
our group, which was not found in the AR constructed by 
Simental et al., is the portion from amino acid 660 to 683. 
One could speculate on the importance of this portion for 
the non-activation of the AR in the absence of androgen, 
and for the HSP90 binding. However, Marivoet et al, 
(1992), using HSP90 antibodies, directly indicated that a 
specific sub-region of the carboxy-terminal half of the rat 
AR (from residues 720 to 774 in the human AR) was re- 
quired for the interaction with HSP90. Thirdly, the differ- 
ence in constitutive transcriptional activity may be related 
to a change in the interaction of the deleted AR with tran- 
scription factors because of the 76 foreign C-terminal 
amino acids resulting from the frameshift. Pierrat et al. 
(1994) described a region of the human estrogen receptor, 
AF-2a, that contains an autonomous activation, which is 
highly conserved in the steroid receptor and located 
within positions 673-693 in the human AR, a region pre- 
sent in our mutant. This domain interacts with hTAFn-30, 
a human TATA-binding protein-associated factor (Jacq et 
al., 1994). It has been suggested by the authors that the 
activating domain constituted by the AF-2a region of 
steroid receptors interacts with both basal transcription 
factors and hTAFn30 for the transcriptional activation. 
The deleted AR would thus be transcriptionally active. 
The abnormal C-terminal domain would be able to cover 
the AF-2a region and inhibit the binding of hTAF,-30 to 
this region, leading to an inactive AR (Fig. 6). To confirm 
this hypothesis, which may highlight the receptor defect 
at the molecular level, the use of antibodies against 
hTAFn-30 would be useful for studying the abnormal 
interaction between the deleted AR and this transcription 
factor. 
In conclusion, as previously claimed by several inves- 
tigators, androgen resistance could serve as a privileged 
model for analyzing the molecular action of androgens 
within target cells. This new deletion in the androgen- 
binding domain, even though it introduces a frameshift, 
provides more insight into the mechanisms leading to 
androgen-regulated gene transactivation. Our data high- 
light the complexity of the genetic mechanisms leading to 
androgen insensitivity. 
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